A detailed history of China Universal Asset Management Co., Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 22,482 shares of ARQT stock, worth $223,246. This represents 0.02% of its overall portfolio holdings.

Number of Shares
22,482
Previous 13,601 65.3%
Holding current value
$223,246
Previous $126,000 65.87%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$8.32 - $11.0 $73,889 - $97,691
8,881 Added 65.3%
22,482 $209,000
Q2 2024

Jul 19, 2024

SELL
$7.24 - $12.53 $36,294 - $62,812
-5,013 Reduced 26.93%
13,601 $126,000
Q1 2024

Apr 29, 2024

BUY
$3.25 - $11.77 $25,005 - $90,558
7,694 Added 70.46%
18,614 $184,000
Q4 2023

May 21, 2024

SELL
$1.84 - $4.82 $14,156 - $37,085
-7,694 Reduced 41.33%
10,920 $35,000
Q4 2023

Jan 23, 2024

BUY
$1.84 - $4.82 $17,167 - $44,970
9,330 Added 586.79%
10,920 $35,000
Q3 2023

May 21, 2024

BUY
$5.31 - $10.98 $4,168 - $8,619
785 Added 97.52%
1,590 $8,000
Q3 2023

Oct 30, 2023

BUY
$5.31 - $10.98 $4,168 - $8,619
785 Added 97.52%
1,590 $8,000
Q2 2023

May 21, 2024

SELL
$7.51 - $15.0 $172 - $345
-23 Reduced 2.78%
805 $7,000
Q2 2023

Jul 27, 2023

SELL
$7.51 - $15.0 $172 - $345
-23 Reduced 2.78%
805 $8,000
Q1 2023

May 21, 2024

BUY
$10.23 - $17.14 $2,138 - $3,582
209 Added 33.76%
828 $9,000
Q1 2023

Apr 27, 2023

BUY
$10.23 - $17.14 $2,138 - $3,582
209 Added 33.76%
828 $9,000
Q4 2022

May 21, 2024

SELL
$13.96 - $20.4 $251,210 - $367,098
-17,995 Reduced 96.67%
619 $9,000
Q4 2022

Jan 31, 2023

BUY
$13.96 - $20.4 $781 - $1,142
56 Added 9.95%
619 $9,000
Q3 2022

Oct 21, 2022

BUY
$17.85 - $26.95 $10,049 - $15,172
563 New
563 $11,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $598M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.